Compare prices and buy Crystagen from 1 research peptide vendor - also called suppliers or sources. Updated daily.
A synthetic peptide from Vladimir Khavinson's short-peptide program, listed in its developers' review as the tripeptide Glu-Asp-Pro (EDP) and as an immunoprotector, though the name has no PubChem record and almost no literature outside that group. Their studies of the aging spleen report that it activates B cells. Not FDA-approved.
For research purposes only. Not medical advice.
Crystagen is a synthetic tripeptide, Glu-Asp-Pro (glutamyl-aspartyl-proline, written EDP), from Vladimir Khavinson's short-peptide program. The rest of the family is in Longevity and Bioregulators. US patent 8,057,810, granted in 2011 from a 2006 Russian application, names Khavinson and three co-inventors and claims the peptide H-Glu-Asp-Pro-OH. Its synthesis example prepares it as an acetate salt and gives the formula C14H21N3O8 and a molecular weight of 359.33 without the counterion. PubChem's compound record for the sequence gives the same formula and does not carry the name Crystagen.
The same three residues end two separate tetrapeptides from the program, Cortagen and Prostamax. The Thymalin page covers the paper that names Glu-Asp-Pro among the calf thymus extract's components.
The developers assign it to the immune system. The patent, titled for a peptide "revealing an immunogeroprotective effect", names age-related disorders of cellular and humoral immunity as its subject. The group's 2022 review in the International Journal of Molecular Sciences lists Crystagen (EDP) as an immunoprotector, citing that patent, in a table that scores how well short peptides fit the amino-acid transporter LAT1 in a computer docking model. Its 2021 review in Molecules, whose table lists Vilon, Ovagen and other members of the family, has no entry for EDP or Crystagen.
All of this is cell, tissue or animal work by the developers and their co-authors, and the first five items are examples in the patent.
The patent's last example describes 38 people aged 62 to 83 with long-term exposure to low-dose ionizing radiation and a decline in immune status, who received the peptide alongside conventional treatment, and 32 controls given conventional treatment alone. It reports that disordered immune measures normalized in 82% of the peptide group against 56% of controls, with the clearest changes in T-lymphocyte measures (CD3+ and CD4+ counts and the CD4/CD8 ratio). The patent does not say how patients were assigned, and the report is a patent example, not a registered trial or a journal article.
PeptideScouter found no US regulatory record for Crystagen or the tripeptide Glu-Asp-Pro. As of October 22, 2026, neither appears in any of these:
The US patent described above is an intellectual-property grant and implies no approval.
Crystagen is the tripeptide Glu-Asp-Pro, written EDP, or glutamyl-aspartyl-proline in full. Its developers' US patent and PubChem's compound record for the sequence give the formula C14H21N3O8 and a molecular weight of about 359.3. The same three residues end Cortagen and Prostamax, separate tetrapeptides from the same research program. With no CAS number in PeptideScouter's records, the sequence and formula are what a certificate of analysis can be checked against.
Because its developers assign it there. Vladimir Khavinson and his co-inventors patented the tripeptide Glu-Asp-Pro as a peptide with an immunogeroprotective effect, for age-related disorders of cellular and humoral immunity, and the group's 2022 review lists Crystagen as an immunoprotector. The patent's experiments use thymus and spleen tissue from old rats, macrophages from aging mice and a rat model of radiation-induced premature aging, and a 2014 paper from the group reports that it activates B cells in the aging spleen. All of this is cell, tissue and animal work. A vendor description PeptideScouter indexes places it in connective and structural tissue research.
Only in a report from its developers that is not a registered trial. Their US patent describes 38 people aged 62 to 83 with long-term exposure to low-dose ionizing radiation who received the tripeptide Glu-Asp-Pro alongside conventional treatment, and 32 controls given conventional treatment alone, and reports that disordered immune measures normalized in 82% of the first group against 56% of controls. The patent does not say how patients were assigned. ClinicalTrials.gov lists no study of it as of October 2026, and its other published experiments are cell, tissue and animal work.
PeptideScouter found no US regulatory record for it. As of October 22, 2026, Crystagen does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings. FDA's substance registry has no record of it, ClinicalTrials.gov lists no study of it and no FDA warning letter names it. A US patent on the peptide, granted in 2011, is an intellectual-property grant and not an approval.
Crystagen is sold by 1 research peptide vendor indexed on PeptideScouter, with 1 tracked listing compared per vendor in the table above. Pricing is normalized and refreshed daily.
Crystagen is currently out of stock across all 1 tracked vendor. The comparison table shows last-seen pricing for reference, and stock state is refreshed daily.
ION Peptide currently lists Crystagen at $2.95/mg (currently out of stock), the lowest listed price across 1 tracked research peptide vendor. With current vendor discount codes applied, the lowest effective price is $2.51/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 1 vendor listing Crystagen publish a PeptideScouter code, worth 15% off. Applied, the lowest effective price falls from $2.95/mg listed to $2.51/mg at ION Peptide. Each vendor's code is shown beside its price in the table above.
1 research peptide vendor currently lists Crystagen on PeptideScouter. We track 1 listing across size and kit variants.
